- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Drug Pipelines
- April 2024
- 180 Pages
Global
From €2900EUR$3,000USD£2,491GBP
- Report
- November 2022
- 154 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Drug Pipelines
- February 2018
- 440 Pages
Global
From €2320EUR$2,400USD£1,993GBP
- Report
- June 2020
- 753 Pages
Global
From €3190EUR$3,300USD£2,740GBP
- Report
- August 2022
- 240 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- January 2022
- 224 Pages
Global
From €6719EUR$6,950USD£5,771GBP
- Report
- August 2022
- 115 Pages
Global
From €4351EUR$4,500USD£3,737GBP
- Report
- April 2021
- 74 Pages
Global
€21269EUR$22,000USD£18,269GBP
- Drug Pipelines
- March 2019
- 111 Pages
Global
€9668EUR$10,000USD£8,304GBP
- Report
- March 2019
- 20 Pages
Global
€9668EUR$10,000USD£8,304GBP
- Report
- March 2019
- 24 Pages
Global
€9668EUR$10,000USD£8,304GBP
- Report
- March 2019
- 19 Pages
Global
€9668EUR$10,000USD£8,304GBP
- Report
- September 2019
- 29 Pages
Global
€9668EUR$10,000USD£8,304GBP
- Report
- August 2018
- 91 Pages
Global
From €2896EUR$2,995USD£2,487GBP
- Drug Pipelines
- February 2020
- 66 Pages
Global
From €3384EUR$3,500USD£2,906GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €483EUR$500USD£415GBP
- Report
- January 2019
- 35 Pages
Global
From €967EUR$1,000USD£830GBP
- Report
- March 2019
- 30 Pages
Global
€9668EUR$10,000USD£8,304GBP
Sutent (sunitinib) is an oncology drug used to treat certain types of cancer, including gastrointestinal stromal tumors (GIST), advanced renal cell carcinoma (RCC), and pancreatic neuroendocrine tumors (PNET). It is a small molecule tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Sutent is typically administered orally, and is available in both capsule and tablet form.
Sutent is a widely used drug in the oncology market, and is often prescribed as a first-line treatment for certain types of cancer. It is also used in combination with other drugs to treat more advanced forms of cancer.
The Sutent market is highly competitive, with many companies offering similar products. Some of the major players in the market include Pfizer, Novartis, Merck, and AstraZeneca. Show Less Read more